Urvi A. Shah, MD
Myeloma Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Multiple myeloma and other plasma-cell diseases
- Smoldering multiple myeloma (SMM)
- Monoclonal gammopathy of undetermined significance (MGUS)
My Specialties
- Clinical trials
- Immunotherapy
- Healthy dietary changes
About Me
- Assistant Attending Physician
I am a board-certified hematologist-oncologist with expertise in diagnosing and treating plasma cell disorders. These include multiple myeloma, smoldering myeloma, and monoclonal gammopathy of undetermined significance (MGUS), among others. At Memorial Sloan Kettering Cancer Center (MSK), I work as part of a multidisciplinary team that cares for people with these cancers.
Read more
During my oncology fellowship training, I needed chemotherapy for Hodgkin lymphoma. My firsthand experience on the other side of the doctor-patient relationship has helped me relate to patients in a more compassionate and empathic way. I find that clear, effective communication with patients, family members, and doctors can be crucial to prevent unnecessary stress and help with recovery.
I conduct clinical and translational research on plasma cell disorders and am currently involved in several clinical trials that are developing and testing new treatments. At MSK, our patients have access to the latest treatments, including immune-based therapies for plasma cell disorders. Sometimes this access is achieved through a clinical trial, but it can also be part of our standard care. I value patients’ goals for their cancer treatment very strongly. I work closely with them to come up with a care plan that suits their needs and also allows for the best possible treatment strategy.
I believe it is important to treat patients with a holistic approach. Therefore, my research focuses on studying the effect of modifiable risk factors (such as nutrition, obesity, and diabetes) on cancer development or progression (most specifically myeloma). I lead the NUTRIVENTION (nutrition intervention) trials, through which we study the impact of dietary interventions and supplements in plasma cell disorders. We study how these interventions influence insulin resistance, body composition, the gut microbiome, and the immune system to reduce the risk of cancer progression and improve outcomes.
In my free time, I enjoy painting with mixed media, cooking, staying active, and being outdoors, especially hiking trails around New York City.
A myeloma specialist is a doctor with special training in diagnosing and treating myeloma.
Conditions I Treat
- Multiple myeloma and other plasma-cell diseases
- Smoldering multiple myeloma (SMM)
- Monoclonal gammopathy of undetermined significance (MGUS)
My Specialties
- Clinical trials
- Immunotherapy
- Healthy dietary changes
Education
- MD, Grant Medical College
Residencies
- Internal Medicine - Tufts Medical Center
Awards and Honors
- Castle Connolly: Top AAPI Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- American Society of Hematology Scholar Award (2023-2025)
- Castle Connolly: America's Top Doctors (2023)
- Rising Star Award, Castle Connolly (2021, 2022)
- Paul Calabresi K12 Career Development Award for Clinical Oncology, NCI (2021-2024)
- Career Development Award, International Myeloma Society (2021-2023)
- Transdisciplinary Research on Energetics and Cancer (TREC) Training Workshop, National Cancer Institute (NCI, 2021)
- Clinical Research Training Institute (CRTI) Award, ASH (2020)
- Future Leaders in Hematology Award, Celgene (2019)
- Shark Tank Audience Choice Award, Memorial Sloan Kettering Cancer Center (2019)
- Henry L. Moses Prize for Best Clinical Paper, Montefiore Medical Center (2019)
- ASCO/AACR Methods in Clinical Cancer Research Workshop (2018)
- Second Place, Outstanding Fellow Research Award, Albert Einstein College of Medicine and Montefiore Medical Center Research Symposium (2018)
- American Society of Hematology (ASH) Abstract Achievement Award (2017)
- ECOG-ACRIN Young Investigator Symposium Distinction Award for Translational Research (2017)
- Chief Fellow, Hematology Rotation, Montefiore Medical Center (2017)
- Outstanding Emergency Department Resident Award, Tufts Medical Center (2015)
Fellowships
- Adult Cancer Immunotherapy - Memorial Sloan Kettering Cancer Center
- Hematology and Medical Oncology - Montefiore Medical Center & Albert Einstein College of Medicine
Board Certifications
- Internal Medicine
- Medical Oncology
- Hematology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Shah sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Shah
- A Study Comparing a Plant-Based Diet with Supplements and Placebo in People with Monoclonal Gammopathy of Undetermined Significance or Smoldering Multiple Myeloma
- A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
- Clinical Trials Co-Investigated by Dr. Shah
- A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets. Clinical Cancer Research. 2022
Malik M, Sweeney NW, Jafri M, Derkach A, Chmielewski C, Adintori PA, Mailankody S, Korde N, Tan CR, Hassoun H, Hultcrantz M, Hillengass J, McCann SE, Iyengar N, Usmani S, Giralt SA, Landgren O, van den Brink MRM, Ahlstrom J, Lesokhin AM, D’Souza AD, Chimonas S, Shah UA. Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer J. 2022, Apr. PMCID: PMC9021216
Shah UA*, Rögnvaldsson S*, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2021 Sep; PMCID: PMC8719074
Read more
Shah UA, Iyengar N. Plant-Based and Ketogenic Diets As Diverging Paths to Address Cancer: A Review. JAMA Oncol. 2022 Aug 1;8(8):1201-1208
Shah UA. Cancer and coronavirus disease 2019 (COVID-19) - Facing the “C words.” JAMA Oncology. 2020 Sep;6:1330-1331.
Shah UA, Chung E, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat T, Mai Y, Wei Y, Ishida E, Choudhary G, Joseph A, Rice R, Gitego N, Bartenstein M, Goel S, Mantzaris I, Shastri A, Parrish C, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma V, Ye BH, Janakiram M. North American ATLL has a Distinct Mutational and Transcriptional Profile and responds to epigenetic therapies. Blood 2018 Aug 13, PMID: 30104217.
Visit PubMed for a full listing of Dr. Shah’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Urvi A. Shah discloses the following relationships and financial interests:
-
American Society of Clinical Oncology (ASCO)
Professional Services and Activities (Uncompensated) -
American Society of Hematology
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
British Society for Haematology
Professional Services and Activities (Uncompensated) -
Dava Oncology
Professional Services and Activities (Uncompensated) -
HealthTree Foundation
Professional Services and Activities (Uncompensated) -
i3 Health
Professional Services and Activities -
Intellisphere, LLC
Professional Services and Activities -
International Myeloma Foundation
Professional Services and Activities -
Janssen Oncology, Inc.
Professional Services and Activities -
Janssen Research & Development, LLC
Professional Services and Activities
-
Janssen Scientific Affairs, LLC
Professional Services and Activities -
Mashup Media, LLC
Professional Services and Activities -
Medscape
Professional Services and Activities -
MJH Associates
Professional Services and Activities -
Multiple Myeloma Research Foundation
Professional Services and Activities -
Phillips Group Oncology Communications, Inc.
Professional Services and Activities -
Plant Based Health Professionals UK
Professional Services and Activities (Uncompensated) -
Plant Powered Metro New York
Professional Services and Activities (Uncompensated) -
Red Med Ed LLC
Professional Services and Activities -
Sanofi-Aventis U.S. LLC
Professional Services and Activities -
Society for Immunotherapy of Cancer
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].